TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Anteris Technologies Global Corp. ( (AVR) ) has shared an update.
On November 16, 2025, Anteris Technologies Global Corp. announced the 30-day clinical outcomes for its DurAVR® Transcatheter Heart Valve (THV) in 100 patients with severe aortic stenosis and small aortic annuli. The results, presented at the PCR London Valves conference, highlighted the valve’s favorable hemodynamic profile, with no valve-related mortality and a significant reduction in prosthesis-patient mismatch compared to existing commercial devices. These outcomes reinforce the potential of DurAVR® THV in advancing towards commercialization, with implications for improved patient outcomes in the treatment of aortic stenosis.
The most recent analyst rating on (AVR) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.
Spark’s Take on AVR Stock
According to Spark, TipRanks’ AI Analyst, AVR is a Neutral.
Anteris Technologies’ overall stock score is primarily impacted by its poor financial performance, characterized by declining revenue, negative profitability, and cash flow issues. Technical analysis indicates bearish momentum, while valuation metrics highlight ongoing losses and lack of earnings, further weighing down the score.
To see Spark’s full report on AVR stock, click here.
More about Anteris Technologies Global Corp.
Anteris Technologies Global Corp. is a global structural heart company focused on designing, developing, and commercializing innovative medical devices aimed at restoring healthy heart function. The company is known for its lead product, the DurAVR® Transcatheter Heart Valve (THV), which is designed to treat aortic stenosis by mimicking the performance of a healthy human aortic valve. Anteris leverages its patented ADAPT® anti-calcification tissue technology, which has been clinically used for over a decade.
Average Trading Volume: 191,432
Technical Sentiment Signal: Strong Sell
Current Market Cap: $152M
For a thorough assessment of AVR stock, go to TipRanks’ Stock Analysis page.